Presentation ACC 2024 Principal Results from the RELIEVE-HF Trial Presenter: Gregg W. Stone April 06, 2024 REGISTER for free or LOG IN to view this content Heart Failure ACC 2024 Up Next Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024 More slides + Presentation ACC 2024 Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk Presenter: Brian Bergmark April 07, 2024 Presentation ACC 2024 Primary Results from the Phase 2 KARDIA-2 Study Presenter: Akshay Desai April 07, 2024 We Recommend
Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024
Presentation ACC 2024 Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk Presenter: Brian Bergmark April 07, 2024
Presentation ACC 2024 Primary Results from the Phase 2 KARDIA-2 Study Presenter: Akshay Desai April 07, 2024